[go: up one dir, main page]

MX2010001071A - Formas de dosificacion retentivas gastricas pulsatiles. - Google Patents

Formas de dosificacion retentivas gastricas pulsatiles.

Info

Publication number
MX2010001071A
MX2010001071A MX2010001071A MX2010001071A MX2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A MX 2010001071 A MX2010001071 A MX 2010001071A
Authority
MX
Mexico
Prior art keywords
dosage forms
gastric retentive
stomach
administration
acid
Prior art date
Application number
MX2010001071A
Other languages
English (en)
Inventor
Bret Berner
Sui Yuen Eddie Hou
Verne Earle Cowles
Chien-Hsuan Han
Ryan Douglas Fell
Chung-Hong Gu
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of MX2010001071A publication Critical patent/MX2010001071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación para liberación retardada y pulsada de agentes terapéuticos en el estómago. Las formas de dosificación son formas de dosificación retentivas gástricas que logran la liberación del agente terapéutico en el estómago y tracto gastrointestinal superior subsiguiente a la administración de la forma de dosificación. Las formas de dosificación encuentran uso particular en la administración de agentes activos lábiles a ácido tales como inhibidores de bomba de protones, y en el tratamiento de secreción de ácido gástrico tal como enfermedad de reflujo gastroesofágico (GERD) e irrupción ácida nocturna (NAB).
MX2010001071A 2007-07-27 2008-07-25 Formas de dosificacion retentivas gastricas pulsatiles. MX2010001071A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95250107P 2007-07-27 2007-07-27
US96771707P 2007-09-05 2007-09-05
PCT/US2008/009139 WO2009017716A2 (en) 2007-07-27 2008-07-25 Pulsatile gastric retentive dosage forms

Publications (1)

Publication Number Publication Date
MX2010001071A true MX2010001071A (es) 2010-03-09

Family

ID=40219415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001071A MX2010001071A (es) 2007-07-27 2008-07-25 Formas de dosificacion retentivas gastricas pulsatiles.

Country Status (8)

Country Link
US (2) US20090028941A1 (es)
EP (1) EP2192892A2 (es)
JP (1) JP2010534721A (es)
CN (1) CN101888828A (es)
AU (1) AU2008282900B2 (es)
CA (1) CA2694602A1 (es)
MX (1) MX2010001071A (es)
WO (1) WO2009017716A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR20110015650A (ko) * 2008-06-03 2011-02-16 노파르티스 아게 발사르탄의 펄스형 방출
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
WO2010019915A1 (en) 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011146611A1 (en) * 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
BR112013003581B8 (pt) 2010-08-18 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica gastro resistente, que compreende um ou mais sais do ácido algínico, e seu processo de produção
MX346203B (es) 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
EP2661260A4 (en) * 2010-12-29 2014-05-14 Reddys Lab Ltd Dr BENZIMIDAZOLE FORMULATIONS WITH MODIFIED RELEASE
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
CA2900763C (en) 2013-02-13 2021-04-06 Reza Fathi Pharmaceutical compositions for the treatment of helicobacter pylori
BR112017018322A2 (pt) * 2015-02-27 2018-04-17 Cingulate Therapeutics LLC formulação estimulante de liberação tripulsátil
MX378262B (es) * 2015-03-31 2025-03-10 Laboratorios Bago S A Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen.
CN113081991B (zh) * 2015-06-03 2022-07-15 南京三迭纪医药科技有限公司 药品剂型及其使用
JP6657974B2 (ja) * 2016-01-12 2020-03-04 トヨタ紡織株式会社 金属樹脂一体成形品及びその製造方法
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
US10327994B2 (en) * 2016-05-02 2019-06-25 Dose Pack Llc System and methods for customized medicine dosages in a capsule
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018102799A1 (en) * 2016-12-02 2018-06-07 Clexio Biosciences Ltd. Gastric residence system
CN108956912A (zh) * 2017-05-17 2018-12-07 亚宝药业集团股份有限公司 一种硝苯地平缓释片溶出曲线的测定方法
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
CA3067567A1 (en) * 2017-06-16 2018-12-20 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
CA3031412C (en) * 2017-06-16 2020-08-11 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
WO2019246145A1 (en) 2018-06-18 2019-12-26 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020036972A1 (en) * 2018-08-15 2020-02-20 Lyndra, Inc. Systems for enteric delivery of therapeutic agents
CN111141854A (zh) * 2018-11-06 2020-05-12 中国科学院大连化学物理研究所 一种同时提取生物样品中极性和弱极性代谢物的方法
CN110372869B (zh) * 2019-08-24 2021-08-27 思必康（厦门）新材料有限公司 一种聚乙烯醇-肝素聚合物及其制备方法和应用
EP4072533B1 (en) * 2019-12-11 2025-01-22 Evonik Operations GmbH Dosage form comprising an alkaline agent and an enteric coating layer
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
CN117491512A (zh) * 2023-09-27 2024-02-02 江苏慧聚药业股份有限公司 一种兰索拉唑肠溶胶囊耐酸力的测定方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4487327A (en) * 1982-12-21 1984-12-11 Grayson Robert E Locking capsule
WO1988001160A1 (en) * 1986-08-19 1988-02-25 Hughes Raymond J Tamper evident capsule and insert device
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
JP2001527023A (ja) * 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO1999033446A1 (en) * 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6098629A (en) * 1999-04-07 2000-08-08 Endonetics, Inc. Submucosal esophageal bulking device
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CZ2003199A3 (cs) * 2000-06-23 2003-12-17 Teva Pharmaceutical Industries Ltd. Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
JP4633329B2 (ja) * 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド スペーストドラッグデリバリーシステム
CA2449009A1 (en) * 2001-05-29 2002-12-05 Depomed Development, Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
WO2003011255A1 (en) * 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
ITMI20012481A1 (it) * 2001-11-23 2003-05-23 Univ Parma Sistemi modulari per il rilascio controllato di sostanza a controllo spaziale e temporale
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2005020879A2 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
JPWO2007074910A1 (ja) * 2005-12-28 2009-06-04 武田薬品工業株式会社 放出制御固形製剤
EP1973530A2 (en) * 2005-12-30 2008-10-01 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
EP1981465B1 (en) * 2006-01-18 2015-11-04 Intec Pharma Ltd. Method for forming delivery devices for oral intake of an agent

Also Published As

Publication number Publication date
US20160038411A1 (en) 2016-02-11
WO2009017716A2 (en) 2009-02-05
CA2694602A1 (en) 2009-02-05
AU2008282900B2 (en) 2014-05-22
AU2008282900A1 (en) 2009-02-05
JP2010534721A (ja) 2010-11-11
US20090028941A1 (en) 2009-01-29
WO2009017716A3 (en) 2009-07-30
CN101888828A (zh) 2010-11-17
EP2192892A2 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
MX2010001071A (es) Formas de dosificacion retentivas gastricas pulsatiles.
WO2010062688A3 (en) Dosage form for insertion into the mouth
JP2016164165A5 (es)
CY1116050T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν αναστολεα αντλιας πρωτονιου και ενα πρεβιοτικο για τη θεραπευτικη αντιμετωπιση ελκωδων βλαβων του στομαχου και του δωδεκαδακτυλου
WO2009017624A3 (en) Compositions with enhanced bioavailability and fast acting inhibitor of gastric acid secretion
TW200509923A (en) A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
NO20092464L (no) Faste former av rasemisk ilaprazol
WO2006076338A3 (en) Dosage form for treating gastrointestinal disorders
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
HRP20151437T1 (hr) Brzo djelujuä†i inhibitor sekrecije želuäśane kiseline
EP4309722A3 (en) Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
NZ597534A (en) Method for treating a patient in need of aspirin therapy
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
NO20075393L (no) Akarbosebaserte fremgangsmater og utforminger for behandling av kronisk forstoppelse
WO2010038241A3 (en) Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
EA200601286A1 (ru) Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
AU2016277587B2 (en) Buffered upper GI absorption promoter
JP2012041314A5 (es)
RU2015106931A (ru) Лекарственное средство от гастроэзофагеальной рефлюксной болезни
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
RU2007149399A (ru) Способ лечения больных колоректальным раком с метастазами в печень
JP2010529125A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal